Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

The anticonvulsants market

Nature Reviews Drug Discovery volume 9, pages 265–266 (2010)Cite this article

Subjects

An Erratum to this article was published on 01 May 2010

Unmet need in epilepsy

Despite the rapid expansion in the number and type of anticonvulsant drugs over the past two decades, the development of new anticonvulsants for refractory epilepsy is hampered by a lack of knowledge of physiological events that induce different seizure types. Levetiracetam (Keppra; UCB) is a muscarinic receptor agonist that binds to SV2A and is widely regarded as the gold standard treatment for epilepsy. However, when administered as adjunctive therapy for refractory partial epilepsy, levetiracetam has been reported to produce responder rates (≥50% reduction in seizure frequency) of just 40–58%2,3,4. Furthermore, ∼20–30% of patients are reported to suffer from refractory epilepsy, despite trying several medications5, and an estimated 0.7–1.1 million patients with epilepsy across the seven major pharmaceutical markets (US, France, Germany, Italy, Spain, UK and Japan) are currently inadequately treated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Shifting market composition for anticonvulsant drugs.
Figure 2: Sales revenue (2008) of key anticonvulsant brands split by indication.

References

  1. World Health Organization. Epilepsy: key facts. WHO website [online], (2009).

  2. Cereghino, J. J. et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55, 236–242 (2000).

    Article  CAS  Google Scholar 

  3. Beran, R. G. et al. Efficacy and safety of levetiracetam 1000–3000mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Epilepsy Res. 63, 1–9 (2005).

    Article  CAS  Google Scholar 

  4. Morrell, M. J. et al. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. 56, 209–120 (2003).

    Article  CAS  Google Scholar 

  5. Sridharan, R. Epidemiology of epilepsy. Curr. Sci. 82, 664–670 (2002).

    Google Scholar 

  6. Datamonitor. Pipeline and commercial insight: neuropathic pain — evaluation of the current and future market dynamics, DMHC2403 (October 2008).

  7. Pfizer. Press release 21 Jun 2007: Pfizer's Lyrica receives FDA approval for fibromyalgia based on expedited review. Pfizer website [online], (2007).

  8. Datamonitor. Commercial and pipeline insight: fibromyalgia — approvals legitimize condition and expose underserved patient population, DMHC2405 (July 2008).

  9. Takeshima, T. et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache 44, 8–19 (2004).

    Article  Google Scholar 

  10. Sanchez-Perez, R. et al. A descriptive study of migraine in a rural population of Area del Comtat. Rev. Neurol. 28, 373–376 (1999).

    CAS  PubMed  Google Scholar 

  11. Silberstein, S. D., Neto, W., Schmitt, J. & Jacobs, D. for the MIGR-001 Study Group. Topiramate in migraine prevention: results of a large, controlled trial. Arch. Neurology 61, 490–495 (2004).

    Article  Google Scholar 

  12. MIDAS sales data and Prescribing Insight. (IMS Health, 2009).

  13. Datamonitor. Commercial insight: anticonvulsants — non-epilepsy indication expansions provide blockbuster potential, DMHC2544 (October 2009).

Download references

Author information

Authors and Affiliations

  1. Charlotte Mackey is a pharmaceuticals and healthcare analyst with Datamonitor, 119 Farringdon Road, London EC1R 3ER, UK. cmackey@datamonitor.com ,

    Charlotte Mackey

Authors
  1. Charlotte Mackey
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mackey, C. The anticonvulsants market. Nat Rev Drug Discov 9, 265–266 (2010). https://doi.org/10.1038/nrd3076

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3076

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research